Mazdutide for type 2 diabetes with fatty liver after semaglutide
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests a new once-weekly injection called Mazdutide for people with type 2 diabetes and moderate-to-severe fatty liver who are already taking semaglutide. The goal is to see if it can improve fatty liver and blood sugar control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 60 years old
- You have type 2 diabetes
- You have been taking once-weekly semaglutide 1.0 mg for at least 16 weeks
- You have moderate-to-severe fatty liver (confirmed by a special scan)
- Your blood sugar (HbA1c) is below 7%
- Your body mass index (BMI) is 24 or higher
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a weekly injection called semaglutide with a calorie-restricted diet to see which helps control blood sugar better. If you have just been diagnosed with type 2 diabetes and have overweight, this trial might help you choose a treatment path.
This study tests if the medication semaglutide helps adults with overweight or obesity lose weight safely. It includes people with or without type 2 diabetes, and aims to see how well the drug works in a Bangladeshi population.
This study tests a new medication (mazdutide) to see if it can help people with type 2 diabetes achieve remission (normal blood sugar levels without needing diabetes medications). It is for adults with type 2 diabetes who are not well controlled on their current treatment (which can be diet and exercise alone, or metformin or an SGLT2 inhibitor). The study will last for a period of time, and participants will receive either the study drug or a placebo (inactive substance).
This study tests whether combining two medications—CS0159 and semaglutide—can safely treat fatty liver disease, type 2 diabetes, and obesity together. If it works, it may help reduce liver fat and improve blood sugar control while supporting weight loss.
This study tests a once-weekly injection called mazdutide to help adults with prediabetes and higher weight lower their blood sugar and potentially lose weight. It is a double-blind, placebo-controlled trial, meaning some people get the real drug and some get a placebo (no active drug).
This study looks at whether the oral medication semaglutide can help treat chronic kidney disease in people who have both type 2 diabetes and a fatty liver related to metabolism. It aims to see if the drug can improve kidney function and liver health.
Hear when a new Type 2 Diabetes Mellitus (T2DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.